GE HealthCare Reports Strong Q3 2026 Results and Raises Full-Year Guidance
GE HealthCare (GEHC) delivered robust third-quarter results, reporting $5.5 billion in revenue with 6.2% organic growth across all business segments. The company saw a significant increase in adjusted EPS to $1.34, up 25.1% year-over-year, supported by an expanded adjusted EBIT margin of 16.6%. Growth was primarily driven by strong performance in pharmaceutical diagnostics and imaging solutions, alongside a substantial backlog increase to $23.7 billion. Following these results, management raised its full-year guidance for organic revenue, adjusted EBIT margins, and adjusted EPS. The company also highlighted the strategic acquisition of SOFIE Bioscience for $945 million, which is expected to bolster its radiopharmaceutical supply footprint in the U.S. While inflationary costs for memory chips and higher oil prices presented headwinds, overall operational profitability and improved free cash flow remain strong.
Topics: Acquisition EPS Increase Free Cash Flow Organic Orders Revenue Growth